Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,609 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorder (MDD) Clear all

Conditions: Major Depressive Disorder
Interventions: Sudarshan Kriya Yoga; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 67 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Placebo, NRX-1074 375 mg, NRX-1074 500 mg, NRX-1074 750 mg; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depression
Interventions: escitalopram, interpersonal psychotherapy; Drug · Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Conditions: Depressive Disorder
Interventions: orvepitant, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 23 more

Conditions: Depression, Major Depressive Disorder
Interventions: Transcranial Light Therapy, Sham Transcranial Light Therapy; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Orangeburg, New York

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 52
States / cities: Imperial, California • Los Angeles, California • Murrieta, California + 46 more

Conditions: TBI, Major Depression, Other Psychiatric Disorders
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
Interventions: Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only; Combination Product
Lead sponsor: Anthony P King; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Atypical Depression
Interventions: Escitalopram; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depression
Interventions: Psilocybin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more

Conditions: Depressive Disorder, Major
Interventions: Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Beverly Hills, California • Burbank, California • Encino, California + 19 more

Conditions: Major Depressive Disorder, Neuroticism, Cognitive Change, Stress
Interventions: Sertraline, bupropion, desvenlafaxine; Drug
Lead sponsor: David Steffens; Other
Eligibility: 65 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Major Depressive Disorder 1
Interventions: Pharmacogenetic testing; Genetic
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Major Depressive Disorder
Interventions: Lurasidone 20 mg, Lurasidone 60 mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 27
States / cities: Birmingham, Alabama • Imperial, California • National City, California + 21 more

Conditions: Migraine, Major Depressive Disorder
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more

Conditions: Mood Disorder, Bipolar Disorder, Major Depression, Depression
Interventions: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Davis, California

Conditions: Major Depressive Disorder
Interventions: Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Depression
Interventions: Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH), Sham Whole-Body Hyperthermia (Sham WBH); Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions: Closed-loop tACS, Sham Comparator; Device
Lead sponsor: Pulvinar Neuro, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alcoholism, Depression
Interventions: NALTREXONE, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 55 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression
Interventions: Paroxetine, Bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Affective Disorders, Psychotic, Depressive Disorder
Interventions: Mifepristone (RU-486), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions: Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Multicomponent Yoga Intervention for Major Depressive Disorder

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

Treatment Choices for Improving Adherence and Outcome

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

Mindfulness-based Psilocybin Therapy for PTSD

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Predictors of Cognitive Outcomes in Geriatric Depression

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Major Depressive Disorder With Mixed Features

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression

Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home

HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2

Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder

Treating Alcohol Use In Older Adults With Depression

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

Treatment of Psychotic Major Depression With Mifepristone

Open-Label Psilocybin Study in Transdiagnostic Population